84-3699-41　GFAP, CT (Glial Fibrillary Acid Protein, Glial Marker, Glial Filament Protein) (PE) 100ul　301364-PE

特徴

• GFAP is one of the major intermediate filament proteins of mature astrocytes.
• GFAP is used as a marker to distinguish astrocytes from other glial cells during development.
• GFAP is expressed in the central nervous system in astrocyte cells and ependymal cells and in cells lacking fibronectin.
• GFAP has also been found to be expressed in glomeruli and peritubular fibroblasts taken from rat kidneys Leydig cells of the testis in both hamsters and humans, human keratinocytes, human osteocytes and chondrocytes and stellate cells of the pancreas and liver in rats.
• Mutations in GFAP expression cause Alexander disease, a rare disorder of astrocytes in the central nervous system.
• Alexander disease, also known as fibrinoid leukodystrophy, is a slowly progressing and fatal neurodegenerative disease.
• It is a very rare disorder which results from a genetic mutation and mostly affects infants and children, causing developmental delay and changes in physical characteristics.
• GFAP is a member of the intermediate filament family.
• GFAP is Phosphorylated by PKN1.
• Applications:Suitable for use in Flow Cytometry (Not Tested), Western Blot and Immunohistochemistry.
• Other applications not tested.
• Recommended Dilution:Flow Cytometry (Not Tested): 1:200-1:500Western Blot: 1:500-1:1000Immunohistochemistry: 1:100-1:200Optimal dilutions to be determined by the researcher.
• Storage and Stability:Store product at 4°C in the dark.
• DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• Caution: PE conjugates are sensitive to light.
• For maximum recovery of product, centrifuge the original vial prior to removing the cap.
• Note: Applications are based on unconjugated antibody.